Heart Failure Reviews

, Volume 18, Issue 4, pp 429–437

Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction

  • Vikram Agarwal
  • Alexandros Briasoulis
  • Franz H. Messerli
Article

Abstract

Heart failure with preserved ejection fraction (HF-PEF) is a well-recognized complication of long-standing hypertension. However, beyond the control of the traditional cardiovascular risk factors, there are few other recommendations for its management. To examine the potential benefit of renin-angiotensin system (RAS) inhibition in HF-PEF, we performed a systematic review of the published medical literature. MEDLINE, EMBASE, and COCHRANE databases were searched from 1966 to 2011 for longitudinal studies examining HF-PEF patients receiving treatment with RAS inhibitors, either ACE inhibitors (ACE-I) or angiotensin receptor blockers (ARB) in addition to their standard treatment compared to those receiving standard treatment alone. We examined the all-cause mortality, cardiovascular mortality, and hospitalizations for heart failure. A total of 12 studies with 11,259 participants were included in the analysis. Among the randomized clinical trials, with the use of RAS inhibitors over standard treatment, there was no improvement in all-cause mortality (RR: 0.99; 95 % CI: 0.88–1.12; p = 0.88), while there was a trend toward lowered rates of hospitalization (RR: 0.93; 95 % CI: 0.86–1.01; p = 0.08). There were no major differences in the outcomes between the ACE-I or ARB. However, among the observational studies with the use of RAS inhibitors, there was a significant benefit in all-cause mortality (RR: 0.76; 95 % CI: 0.62–0.93; p = 0.009), with no significant impact on the hospitalization rates. RAS inhibition in HF-PEF was not associated with significant reduction in all-cause or cardiovascular mortality, but randomized control trials appear to demonstrate a trend toward reduction in the risk for subsequent hospitalization. Further prospective randomized trials are warranted to confirm the effects of RAS inhibition on mortality and hospitalization.

Keywords

ACE inhibitors Angiotensin receptor blockers Heart failure with preserved ejection fraction Meta-analysis 

References

  1. 1.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. doi:10.1056/NEJMoa052256 PubMedCrossRefGoogle Scholar
  2. 2.
    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345. doi:10.1093/eurheartj/ehl250 PubMedCrossRefGoogle Scholar
  3. 3.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362(9386):777–781. doi:10.1016/S0140-6736(03)14285-7 PubMedCrossRefGoogle Scholar
  4. 4.
    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467. doi:10.1056/NEJMoa0805450 PubMedCrossRefGoogle Scholar
  5. 5.
    Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE (2008) The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94(5):573–580. doi:10.1136/hrt.2007.117978 PubMedCrossRefGoogle Scholar
  6. 6.
    Zi M, Carmichael N, Lye M (2003) The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 17(2):133–139PubMedCrossRefGoogle Scholar
  7. 7.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12PubMedCrossRefGoogle Scholar
  8. 8.
    Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982–989PubMedCrossRefGoogle Scholar
  9. 9.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRefGoogle Scholar
  10. 10.
    Demets DL (1987) Methods for combining randomized clinical trials: strengths and limitations. Stat Med 6(3):341–350PubMedCrossRefGoogle Scholar
  11. 11.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186 PubMedCrossRefGoogle Scholar
  12. 12.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCrossRefGoogle Scholar
  13. 13.
    Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463PubMedCrossRefGoogle Scholar
  14. 14.
    Philbin EF, Rocco TA Jr (1997) Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 134(2 Pt 1):188–195PubMedCrossRefGoogle Scholar
  15. 15.
    Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL (2000) Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109(8):605–613PubMedCrossRefGoogle Scholar
  16. 16.
    Grigorian Shamagian L, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR (2006) Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail 12(2):128–133. doi:10.1016/j.cardfail.2005.09.001 PubMedCrossRefGoogle Scholar
  17. 17.
    Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M (2008) Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 101(5):639–644. doi:10.1016/j.amjcard.2007.10.026 PubMedCrossRefGoogle Scholar
  18. 18.
    Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM (2001) Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail 7(3):221–228. doi:10.1054/jcaf.2001.26896 PubMedCrossRefGoogle Scholar
  19. 19.
    Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF (2002) Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 144(2):365–372PubMedCrossRefGoogle Scholar
  20. 20.
    Sueta CA, Russo A, Schenck A, Brown DW, Simpson RJ (2003) Effect of angiotensin-converting inhibitor or angiotensin receptor blocker on one-year survival in patients > or =65 years hospitalized with a left ventricular ejection fraction > or =50 %. Am J Cardiol 91(3):363–365PubMedCrossRefGoogle Scholar
  21. 21.
    Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482–1487. doi:10.1161/CIRCULATIONAHA.107.696906 PubMedCrossRefGoogle Scholar
  22. 22.
    Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA (2007) Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49(2):198–207. doi:10.1016/j.jacc.2006.08.050 PubMedCrossRefGoogle Scholar
  23. 23.
    Tartiere-Kesri L, Tartiere JM, Logeart D, Beauvais F, Cohen Solal A (2012) Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 59(5):455–461. doi:10.1016/j.jacc.2011.10.873 PubMedCrossRefGoogle Scholar
  24. 24.
    Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M (2000) Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 47(2):274–283PubMedCrossRefGoogle Scholar
  25. 25.
    Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S (2006) Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 48(1):80–86. doi:10.1161/01.HYP.0000224283.76347.8c PubMedCrossRefGoogle Scholar
  26. 26.
    Packer M (2011) Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail 4(5):538–540. doi:10.1161/CIRCHEARTFAILURE.111.963710 PubMedCrossRefGoogle Scholar
  27. 27.
    Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. Eur Heart J 28(20):2539–2550. doi:10.1093/eurheartj/ehm037 PubMedCrossRefGoogle Scholar
  28. 28.
    Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22(2):107–133. doi:10.1016/j.echo.2008.11.023 PubMedCrossRefGoogle Scholar
  29. 29.
    Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the councils on clinical cardiology and epidemiology and prevention. Circulation 115(21):2761–2788. doi:10.1161/CIRCULATIONAHA.107.183885 PubMedCrossRefGoogle Scholar
  30. 30.
    Lee TT, Chen J, Cohen DJ, Tsao L (2006) The association between blood pressure and mortality in patients with heart failure. Am Heart J 151(1):76–83. doi:10.1016/j.ahj.2005.03.009 PubMedCrossRefGoogle Scholar
  31. 31.
    Ather S, Chan W, Chillar A, Aguilar D, Pritchett AM, Ramasubbu K, Wehrens XH, Deswal A, Bozkurt B (2011) Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J 161(3):567–573. doi:10.1016/j.ahj.2010.12.009 PubMedCrossRefGoogle Scholar
  32. 32.
    Lee DS, Ghosh N, Floras JS, Newton GE, Austin PC, Wang X, Liu PP, Stukel TA, Tu JV (2009) Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail 2(6):616–623. doi:10.1161/CIRCHEARTFAILURE.109.869743 PubMedCrossRefGoogle Scholar
  33. 33.
    Nunez J, Nunez E, Fonarow GC, Sanchis J, Bodi V, Bertomeu-Gonzalez V, Minana G, Merlos P, Bertomeu-Martinez V, Redon J, Chorro FJ, Llacer A (2010) Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure. Eur J Heart Fail 12(1):38–44. doi:10.1093/eurjhf/hfp176 PubMedCrossRefGoogle Scholar
  34. 34.
    Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59(5):442–451. doi:10.1016/j.jacc.2011.09.062 PubMedCrossRefGoogle Scholar
  35. 35.
    Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O’Meara E, Shaburishvili T, Pitt B, Pfeffer MA (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162(6):966–972 e910. doi:10.1016/j.ahj.2011.09.007 Google Scholar
  36. 36.
    Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B (2010) Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 12(8):874–882. doi:10.1093/eurjhf/hfq087 PubMedCrossRefGoogle Scholar
  37. 37.
    Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273(5):408–412PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Vikram Agarwal
    • 1
  • Alexandros Briasoulis
    • 1
  • Franz H. Messerli
    • 2
  1. 1.Department of Medicine, St Luke’s Roosevelt Hospital CenterColumbia University College of Physicians and SurgeonsNew YorkUSA
  2. 2.Hypertension Program, Department of Cardiology, St Luke’s Roosevelt Hospital CenterColumbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations